Integrin signaling plays an important role in cellular proliferation and migration via interactions with extracellular matrix proteins. Prior studies indicate that integrin signaling facilitates tumor invasion and metastasis, and there are several ongoing clinical trials using agents that modulate this pathway. We recently identified clonal enrichment in mutations in the integrin cell surface interactions pathways in advanced urothelial carcinoma. An ideal strategy for investigating integrin signaling is via 3D organoid culture, maintaining intercellular interactions that replicate the epithelial microenvironment. We hypothesize that pharmacologic integrin signaling modulation will impair organoid growth in bladder cancer cells and demonstrate a therapeutic utility for this approach.
INTRODUCTION AND OBJECTIVES:
Integrin signaling plays an important role in cellular proliferation and migration via interactions with extracellular matrix proteins. Prior studies indicate that integrin signaling facilitates tumor invasion and metastasis, and there are several ongoing clinical trials using agents that modulate this pathway. We recently identified clonal enrichment in mutations in the integrin cell surface interactions pathways in advanced urothelial carcinoma. An ideal strategy for investigating integrin signaling is via 3D organoid culture, maintaining intercellular interactions that replicate the epithelial microenvironment. We hypothesize that pharmacologic integrin signaling modulation will impair organoid growth in bladder cancer cells and demonstrate a therapeutic utility for this approach.
METHODS: RT4 human bladder cancer cell line was used as well as a second cell line established from a patient-derived bladder cancer sample (PM748). Cells were grown in 3D organoid culture as previously described. For in vitro integrin modulation, defactinib, an orally-bioavailable selective inhibitor of focal adhesion kinase (FAK, a convergent and conserved enzyme activated by integrin ligand binding), was used. SDS-PAGE and immunoblotting were performed to show in vitro FAK inhibition. Single cell suspensions and organoids were plated in the presence of various concentrations of defactinib to determine the impact on organoid formation and regression.
RESULTS: Defactinib caused a dose-dependent decrease in autophosphorylation of FAK for both cell lines, demonstrating effective FAK inhibition. 3D culture of single cells with defactinib produced a dose-dependent decrease in organoid size after 96 hours (mean size for DMSO only, 100nM, 1uM, and 10uM were 128um, 75um, 48um, and 26um, respectively; p<0.0001 versus DMSO for all dilutions). Established organoids showed a dose-dependent regression in size after 72 hours of defactinib exposure (mean size for DMSO, 100nM, 1uM, and 10uM were 225um, 96um, 70um, and 34um, respectively; p<0.0001 versus DMSO). Experiments utilizing Crispr-Cas9-mediated FAK knock-out as well as in vivo studies with FAK inhibitors in xenograft models are currently underway.
CONCLUSIONS: Integrin modulation via FAK inhibition with defactinib causes both inhibition of organoid formation as well as regression of formed organoids, and the effects are seen at concentrations well below the cytotoxic range for the drug. This study suggests a utility for these agents in bladder cancer treatment. decrease in bladder cancer recurrence in patients on a high dose antioxidant vitamin regimen. In a previous integrative analysis of TCGA methylation data, we found genes in the Nrf2 pathway, an important regulatory pathway in response to oxidative stress, to be hyper-methylated and thus down regulated in bladder cancer. We sought to further characterize the activity of Nrf2 pathway gene expression in normal urothelium, and urothelium with non-muscle invasive and muscle invasive cancer.
METHODS: We identified a publically available gene expression microarray dataset using the gene expression omnibus (GSE 3167) that included 10 patients with normal urothelium, 15 patients with stage Ta urothelial carcinoma, 8 patients with carcinoma in situ, and 13 patients with muscle invasive disease. We used the Nrf2 pathway signature discovered in our initial analysis. We evaluated the clustering of samples according to the Nrf2 pathway in an unsupervised pathway using the heatmap.2 function in R.
RESULTS: Our clustering analysis on an independent dataset showed that the Nrf2 signature separates urothelial carcinoma from normal samples. The genes driving this clustering included KEAP1, GPX3, PGO, and TXN, all of which had higher levels of expression in normal tissue compared with tumor tissue, consistent with downregulation of Nrf2 dependent genes in tumor tissue. There did appear to be some independent clustering of low grade and muscle invasive disease, but this was less pronounced than the clustering of normal urothelium versus urothelial carcinoma.
CONCLUSIONS: This study corroborates prior findings and shows that genes in the Nrf2 pathway are inactivated in urothelial carcinoma. The expression of Nrf2 genes was decreased in patients with urothelial carcinoma. The lack of clear clustering among different stages of disease suggests that decreased expression of genes in the Nrf2 pathway is an early event in the pathogenesis of urothelial carcinoma. Our data demonstrate a biochemical description of the pathway by which antioxidant mechanisms may affect progression of urothelial carcinoma.
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